AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Stromal cell-derived factor 1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P48061

UPID:

SDF1_HUMAN

Alternative names:

C-X-C motif chemokine 12; Intercrine reduced in hepatomas; Pre-B cell growth-stimulating factor

Alternative UPACC:

P48061; B2R4G0; E7EVL0; H7BYN8; Q2L985; Q2L986; Q2L988; Q5IT36; Q6ICW0; Q9H554

Background:

Stromal cell-derived factor 1 (SDF-1), also known as C-X-C motif chemokine 12, plays a pivotal role in chemotaxis, acting as a chemoattractant for T-lymphocytes and monocytes. It activates the CXCR4 receptor, inducing calcium ion mobilization and cell migration. SDF-1's interaction with integrins and the atypical chemokine receptor ACKR3 highlights its complex regulatory functions in cellular signaling and migration, essential for both immune responses and developmental processes.

Therapeutic significance:

Understanding the role of Stromal cell-derived factor 1 could open doors to potential therapeutic strategies. Its involvement in monocyte migration and adhesion, as well as its protective role after myocardial infarction, underscores its potential as a target for therapeutic intervention in cardiovascular diseases and immune modulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.